Avant Immunotherapeutics Incorporated

News and Blogs

Medarex posts wider 2Q loss on lower revenue (AP)

biz.yahoo.com | Aug 6, 2008

Medarex posts wider 2Q loss on lower revenue. - PRINCETON, N.J. (AP) -- Biotechnology company Medarex Inc. said late Tuesday its second-quarter loss widened on a mix of lower revenue and a charge related to its affiliate Avant Immunotherapeutics.

http://biz.yahoo.com/ap/080806/earns_medarex.html?.v=1

Can Citi's Pandit last the year?

www.bloggingstocks.com | Jul 16, 2008

Filed under: Earnings reports, Citigroup Inc. (C)<img vspace="4" hspace="4" border="1" align="right" alt=""

http://www.bloggingstocks.com/2008/07/16/can-citis-pandit-last-the-year/

Biotech Stocks: Drug stocks edge higher; Genentech retreats

www.marketwatch.com | Jun 3, 2008

Drug stocks inch higher, with shares of Schering-Plough climbing as its polio drug compound begins testing.

http://www.marketwatch.com/enf/rss.asp?guid=%7B6E8099FB-58DD-4049-A987-5C5BBC1F3581%7D&siteid=rss&rss=1

Pfizer 1Q profit falls on buyout charges, patent losses

www.newsvine.com | Apr 17, 2008

Pfizer Inc., the world's biggest drugmaker, reported an 18 percent drop Thursday in its first-quarter profit on tougher generic competition but said it still expects to meet profit expectations for the full-year.

http://www.newsvine.com/_news/2008/04/17/1436178-pfizer-1q-profit-falls-on-buyout-charges-patent-losses

Web Sites

Total : 3 View more »

Avant Immunotherapeutics Incorporated

SAN DIEGO, Calif. -- – ICON Group International Ltd., today released two economic analyses on labor productivity and financial benchmarks for Avant Immunotherapeutics Incorporated (NAS: AVAN).

http://www.icongrouponline.com/pr/Avant_Immunotherapeutics_Incorporated_US/PR.html

Avant Immunotherapeutics

News Resources Jobs Companies Diseases Events Experts News Breaking News By Subject Archive BioBuzz Newsletters Biospace Forums Hotbed Communities Bio NC™ BioCapital™ BioForest™ new BioMidwest™ BioGarden™ (NJ) Biotech Bay™ Biotech Beach™ Genetown™ Pharm Country™ Southern Pharm™ new Career Center

http://www.biospace.net/company_profile.aspx?CompanyId=4153

Avant Immunotherapeutics - Analyst News | newratings.com

Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.

http://www.newratings.com/headlines/Avant-Immunotherapeutics_US0534911062.html

News from Zibb.com

Total : 1 View more »

Avant Immunotherapeutics to change name to Celldex Therapeutics - Zibb.com

Sep 30, 2008 (Datamonitor via COMTEX) --

Avant Immunotherapeutics, an integrated biopharmaceutical company, has announced that, pursuant to a previously announced shareholder vote, the company will change its name to Celldex Therapeutics, effective October 1, 2008.

The board of directors also announced the appointment of Anthony Marucci, who has been serving as interim president and CEO since May 2008, as president and CEO of the company.

Avant Immunotherapeutics and Celldex Therapeutics completed a merger during the first quarter of 2008. The combined company's internal pipeline is fueled by the creation of novel immunotherapy candidates based on Celldex's precision targeted immunotherapy platform, said Avant.

Mr Marucci said: "This change reflects the company's expertise and focus on developing therapeutic vaccines and antibodies, including the APC Targeted Technology platform which is a combination of both and is synonymous with the Celldex name."

Charles Schaller, chairman of the board of Avant Immunotherapeutics, said: "Anthony has demonstrated strong leadership as Celldex has grown both operationally and scientifically. We are confident that under his guidance the company will continue to make rapid progress in the development of new immunotherapy-based treatments for cancer and other serious diseases. On behalf of the board, I am pleased to announce Anthony's appointment and look forward to his continued contributions."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon